Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J K Ostor

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Inflammopharmacology|December 16, 2005
The murky waters of the coxibs: a review of the current state of playAndrew J K Ostor, Brian L Hazleman
The Practitioner|January 26, 2012
Early diagnosis crucial in ankylosing spondylitisAnshuman P Malaviya, Andrew J K Ostor
American Journal of Ophthalmology|March 28, 2006
Orbital cellulitis in a patient receiving infliximab for Ankylosing spondylitisJonathan C P Roos, Andrew J K Ostor
Biologics : Targets & Therapy|August 20, 2021
Biological Therapies for Rheumatoid Arthritis: An Overview for the ClinicianKate E Findeisen, Julia Sewell, Andrew J K Ostor
Cutaneous and Ocular Toxicology|November 17, 2010
Necrotizing group A streptococcal periorbital infection following adalimumab therapy for rheumatoid arthritisJonathan C P Roos, Cornelius René, Andrew J K Ostor
Rheumatology and Therapy|April 1, 2017
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Rheumatology (Oxford, England)|December 1, 2009
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature reviewSarah L Westlake, Alexandra N Colebatch, Janis Baird, et al.
RMD Open|June 14, 2022
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2Andrew J K Ostor, Ahmed M Soliman, Kim A Papp, et al.
Rheumatology (Oxford, England)|November 13, 2010
Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature reviewSarah L Westlake, Alexandra N Colebatch, Janis Baird, et al.
Clinical Rheumatology|January 25, 2012
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidanceYee Chiu, Andrew J K Ostor, Anthony Hammond, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Inflammopharmacology|December 16, 2005
The murky waters of the coxibs: a review of the current state of playAndrew J K Ostor, Brian L Hazleman
The Practitioner|January 26, 2012
Early diagnosis crucial in ankylosing spondylitisAnshuman P Malaviya, Andrew J K Ostor
American Journal of Ophthalmology|March 28, 2006
Orbital cellulitis in a patient receiving infliximab for Ankylosing spondylitisJonathan C P Roos, Andrew J K Ostor
Biologics : Targets & Therapy|August 20, 2021
Biological Therapies for Rheumatoid Arthritis: An Overview for the ClinicianKate E Findeisen, Julia Sewell, Andrew J K Ostor
Cutaneous and Ocular Toxicology|November 17, 2010
Necrotizing group A streptococcal periorbital infection following adalimumab therapy for rheumatoid arthritisJonathan C P Roos, Cornelius René, Andrew J K Ostor
Rheumatology and Therapy|April 1, 2017
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyFilip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, et al.
Rheumatology (Oxford, England)|December 1, 2009
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature reviewSarah L Westlake, Alexandra N Colebatch, Janis Baird, et al.
RMD Open|June 14, 2022
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2Andrew J K Ostor, Ahmed M Soliman, Kim A Papp, et al.
Rheumatology (Oxford, England)|November 13, 2010
Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature reviewSarah L Westlake, Alexandra N Colebatch, Janis Baird, et al.
Clinical Rheumatology|January 25, 2012
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidanceYee Chiu, Andrew J K Ostor, Anthony Hammond, et al.
Pageof 2